Stuart J. Rabin
Chairman of the Board of Managers (Nonexecutive)– Decision Medical; Chairman of the Board of Directors – Decision Sciences International Corporation; President and CEO – Nine Thirty Capital
Stuart J. Rabin is the President and CEO as well as the Chief Investment Officer of Nine Thirty Capital, a diversified investment firm that he launched in 2004. Based in New York, Nine Thirty Capital is a flexible platform that invests in private companies as well as public securities and actively manages customized investment portfolios for prominent families and institutional clients from around the world.
From 1997 through 2008, Mr. Rabin was the President and CEO of JFI, a diversified family investment company that he co-founded. At JFI he constructed and actively managed a series of sizeable bespoke portfolios that included numerous hedge funds, an internal equity trading vehicle, direct private company investments and real estate partnerships.
Previously, Mr. Rabin was employed by a New York based hedge fund, by Morgan Stanley Asset Management and by Bear Stearns & Co. Earlier in his career, Mr. Rabin practiced law with the New York firm of Skadden, Arps, Slate, Meagher & Flom and with the Washington, D.C. firm of Verner, Liipfert, Bernard, McPherson & Hand (now DLA Piper).
Mr. Rabin is the Chairman of the Board of Directors of Decision Sciences International Corporation (www.DecisionSciencesCorp.com), an advanced technology company focused on the critical mission of preventing nuclear terrorism and proliferation. Decision Sciences’ revolutionary and disruptive technology – originally developed in close cooperation with the renowned Los Alamos National Laboratory – can dramatically improve the safety and security of the global community, help to save millions of lives and prevent the economic and psychological devastation likely to result from even a single act of radiological or nuclear terrorism.
Mr. Rabin is also a member of the Board of Directors of 924 Global Asset Finance Corporation and Decision Sciences Medical Company, an affiliate of Decision Sciences focused on bringing to market an advanced medical ultrasound technology for the early, non-invasive detection of cancer and other serious medical conditions.
Nine Thirty Capital’s significant commitment to, and Mr. Rabin’s active involvement in, the business of Decision Sciences is illustrative of his belief that a flexible investment platform can be a model of progressive capitalism. Focusing on “doing good and doing well” can advance societal goals while simultaneously rewarding all stakeholders.
Mr. Rabin devotes substantial time and attention to charitable and civic causes including nonprofit organizations involved in education, promoting active citizenship and illuminating Constitutional ideals, healthcare and international affairs. Mr. Rabin is a member of the Board of Trustees of the New-York Historical Society, the National Constitution Center in Philadelphia, and is Chairman of the New York (Columbia) Presbyterian Health Sciences Advisory Council and Co-Chair of the Council’s Neurosciences Committee. Mr. Rabin is also a member of the Council on Foreign Relations, the Wharton Global Family Alliance of the Wharton School of the University of Pennsylvania, and the International Council of the Belfer Center for Science and International Affairs at the John F. Kennedy School of Government at Harvard University.
Mr. Rabin graduated with honors from Georgetown University and the Georgetown University Law Center. He received his MBA from the Wharton School of the University of Pennsylvania.
Pasquale “Pat” D’Amuro
Board Member; Chairman and Chief Executive Officer – Global Risk & Investigative Diligence, LLC
Pat D’Amuro is the former Chairman and CEO of Giuliani Security & Safety LLC, a division of Giuliani Partners LLC dedicated to security consulting. Previously, Mr. D’Amuro served as the Assistant Director in Charge of the New York FBI Office, where he began his FBI career in 1979. Much of Mr. D’Amuro’s twenty-six year career has been devoted to counterterrorism, in which he is an internationally recognized expert.
After the terrorist attacks of September 11, 2001, Mr. D’Amuro was appointed Inspector in Charge of the FBI’s investigation of those attacks. Subsequently, Mr. D’Amuro served as Assistant Director of the Counterterrorism Division at FBI Headquarters and, later, Executive Assistant Director for Counterterrorism and Counterintelligence. In these capacities, he was instrumental in the creation and management of the FBI’s Terrorism Threat Integration Center and Terrorism Watch List.
During his distinguished career at the FBI, Mr. D’Amuro contributed to or led several high profile investigations, including the investigations of the 1998 bombings of the American Embassies in East Africa and the 2000 attack on the USS Cole in Yemen, as well as the latter stages of the investigations of the 1993 World Trade Center bombing, the Manila Air plot, and the crash of TWA Flight 800. Mr. D’Amuro has provided advice and briefings to the President of the United States, the U.S. Attorney General, the Director of the FBI, and the National Security Council, among others. Mr. D’Amuro also serves as Chair of Decision Sciences’ Board of Advisors.
Board Member; Co-Founder and Managing Partner, Decision Medical Ventures
Ms. Surrey’s experience includes working for a large pharmaceutical company in World Wide Business Development, R&D, and Mergers and Acquisitions. She has managed and closed investments in the pharmaceutical, biotechnology, medical device and diagnostics areas. Ms. Surrey has 12 years of experience working in the life sciences/pharmaceutical industry in the areas of Private Equity Venture Capital, as well as business development for a major pharmaceutical company. She was responsible for managing a portfolio of investments and negotiating global deals in licensing, collaborations, and acquisitions with other pharmaceutical and biotech companies, fund of fund investments, and financial valuations. Ms. Surrey previously worked at a venture capital private equity fund in London, focusing on life sciences in areas of biotechnology, medical devices, therapeutics, and nanotechnology. She also held positions at the Cabinet Office in the Ministry of Science and Technology working on the Global Innovation Forum.
Ms. Surrey graduated summa cum laude with an M.S. Eng. and a M.B. in biomedical engineering and biotechnology, respectively, from University of Pennsylvania, with a joint published thesis from the Library of Congress in robotic surgery with the Engineering School at Oxford University. Samantha holds an undergraduate degree in Engineering and Applied Mathematics from Cornell University.
She has a published paper that was presented at the Engineering and Medicine Society Conference in France with the Jet Propulsion Laboratory and NASA, as well a published thesis on Artificial Muscles and the Applications to Robotic Surgery.
She holds numerous publications as well as a patent in 3-D protein modeling sold to Microsoft for genomics. She has an Executive Finance Degree from Wharton and completed the Private Equity Venture Capital Program at Harvard Business School. She was nominated for the “ Rising Star” award in Science, Women, and Engineering in 2010.
George R. Creel
Board Member; Co-Founder and Managing Partner, Decision Medical Ventures
Mr. Creel is the Co- Founder/Managing Partner of Decision Medical Ventures as well as the Managing Partner of Colesbury Capital. He co-founded Decision Medical Ventures, a New York and California-based life sciences investment firm, with Samantha Surrey. Colesbury Capital was launched in January 2008 and is headquartered in Dallas, Texas. Colesbury® is an alternative investment platform that makes direct public and private company investments through its small cap long/short hedge fund and its middle market private equity investment vehicles. Colesbury also engages in merchant banking activities through its affiliate Colesbury Capital Markets and actively invests in U.S. land-based oil & gas drilling projects through Colesbury Energy Partners.
Prior to founding Colesbury, Mr. Creel was a partner and Managing Director at H.I.G. Capital, a Miami based private equity firm with over $7B in management, and a co-founder of Brightpoint Capital, H.I.G.’s public securities investment affiliate. Prior to joining H.I.G. Capital, Mr. Creel was a partner with a New York based registered investment advisory firm with over $2B in assets under management. These funds consistently provided superior relative and absolute returns for investors and were among the industry’s highest rated performers.
Earlier in his career, Mr. Creel held senior positions in institutional investment banking and brokerage, with the firms of Brown Brothers Harriman & Co. and Deutsche Bank. Over his twenty-five years in the investment business, he has worked extensively within the information technology, telecommunications, and energy sectors. Mr. Creel has served on numerous corporate boards. He currently serves on the DSMC Board of Managers, and as a director of Shapemix LLC, and Knock Inc.
Mr. Creel received his B.A. from Auburn University and is a member of the Chartered Financial Analysts (CFA) Institute and the New York Society of Security Analysts. Additionally, he has participated in post-graduate executive programs at both the Columbia and Harvard Business Schools.